Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
5 Biotech Stocks Under $10 Worthy of Investors' Attention

Small biotech stocks are good bets with lower market cap as well as share price.

MNLO : 7.93 (-0.63%)
SHPG : 172.54 (+0.28%)
CYTR : 1.22 (+1.67%)
KMDA : 5.64 (+0.80%)
BLPH : 2.78 (-0.36%)
SNSS : 2.39 (-0.21%)
SNY : 41.90 (+0.36%)
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp

The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp

SCVL : 32.73 (+0.71%)
OFG : 14.98 (-1.80%)
ECHO : 28.90 (-2.03%)
CMTL : 34.49 (-0.12%)
BLPH : 2.78 (-0.36%)
Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it will participate on a panel, titled Emerging Landscape of...

BLPH : 2.78 (-0.36%)
Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate

With trade-related tensions refusing to die down, small-cap stocks are looking like an increasingly attractive proposition.

SCVL : 32.73 (+0.71%)
OFG : 14.98 (-1.80%)
ECHO : 28.90 (-2.03%)
CMTL : 34.49 (-0.12%)
BLPH : 2.78 (-0.36%)
Bellerophon to Present Positive Results from Phase 2 Study of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from...

BLPH : 2.78 (-0.36%)
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter...

BLPH : 2.78 (-0.36%)
Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that, following the receipt of minutes from a recent meeting with...

BLPH : 2.78 (-0.36%)
Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher

Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

EXAS : 65.00 (+0.53%)
BLPH : 2.78 (-0.36%)
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%

Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

BLPH : 2.78 (-0.36%)
ALXN : 135.42 (+0.62%)
Pick 3 Biotech Money-Spinning Bets Amid Market Instability

The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

OMED : 2.33 (-1.69%)
NVAX : 1.36 (unch)
BLPH : 2.78 (-0.36%)
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will...

BLPH : 2.78 (-0.36%)
Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018

Stock Monitor: Bellerophon Therapeutics Post Earnings Reporting

ICPT : 95.70 (+2.50%)
BLPH : 2.78 (-0.36%)
Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Bellerophon Therapeutics, Inc. (BLPH).

BLPH : 2.78 (-0.36%)
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter...

BLPH : 2.78 (-0.36%)
Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse(R) for Treatment of Pulmonary Arterial Hypertension

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study evaluating INOpulse(R) in patients with pulmonary...

BLPH : 2.78 (-0.36%)
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2017.

BLPH : 2.78 (-0.36%)
Bellerophon Announces $23 Million Private Placement

Financing will support the continued development of the company's INOpulse platform with Phase 3 clinical trials in Pulmonary Arterial Hypertension and Phase 2 trials in Pulmonary Hypertension associated...

BLPH : 2.78 (-0.36%)
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at...

BLPH : 2.78 (-0.36%)
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive top line data from a Phase 2 clinical trial evaluating INOpulse(R) in patients with Pulmonary...

BLPH : 2.78 (-0.36%)
Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse(R) in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced agreement with the U.S. Food and Drug Administration (FDA) on the Phase 2 study design for INOpulse(R)...

BLPH : 2.78 (-0.36%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.75 , CAKE -0.10 , PLT -0.18 , AEO +0.45
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures are currently 3 to 4 cents higher after posting fractional to 2 cent gains in most contracts to start the week. Preliminary open interest was down 3,350 contracts yesterday, suggesting short covering. The USDA Export Inspections report s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar